Intended use -The prevention or reduction in severity of Rhodococcus equi
foal pneumonia by prophylactic treatment. This product is not intended to
treat R. equi pneumonia once clinical signs appear.
Dose & Route of Administration - The route of administration is intravenous
and the dose is 10 ml/lb. The product may be administered once in the first
week of life if conditions favoring R. equi pneumonia exist and may be
repeated at 3 week intervals if warranted in endemic areas where there is a
previous history of R. equi foal pneumonia.
In this year's field trial at an Ocala, Florida thoroughbred farm, we demonstrated a 40% reduction in the incidence of R. equi pneumonia between the foals treated with our Rhodococcus equi Antibody and the controls who received no preventative treatment. We have done more research on the prevention of Rhodococcus equi foal pneumonia than any other company and are sharing our data with University researchers across the country in order to develop a better understanding of this disease.
In combination with these researchers we plan to publish two papers on the subject in the near future. Lake immunogenics as more data on file in support of the efficacy of Rhodococcus equi Antibody than any other manufacturer, therefore we are currently recommending administering two 950 ml doses of Rhodococcus equi Antibody during the time of exposure, depending on local conditions. A general rule for prevention would be to administer the first dose at day 5 and repeat in 3 weeks.
We look forward to discussing your individual situation in helping you developed a prophylactic treatment regime that works for your
clients.